Kidney Cancer Journal 93
References
1. American Cancer Society. Kidney cancer (adult)—renal cell carcinoma.
2014 (http://w.w.w.cancer.org/acs/groups/cid/documents/webcontent/
003107-pdf.pdf).
2. Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial
nephrectomy for localized renal cell carcinoma and management
of recurrent disease. Urol Clin North Am. 2003;30:8843-852.
3. Janowitz T, Welsh S, Zaki K, et al. Adjuvant therapy in renal cell carcinoma
past, present, and future. Semin Oncol. 2013;40:82-491.
4. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients
with metastatic renal cell carcinoma who received high-dose recombinant
interleukin-2 therapy. J Clin Oncol.1995;13:688-696.
5. Pal SK, Haas NB. Adjuvant therapy for renal cell carcinoma: past, present,
and future. Oncologist. 2014;19:851-59.
6. Chamie K, Donin NM, Klöpfer P, et al. Adjjuvant weekly girentuximab
following nephrectomy gor high-risk renal cell carcinoma: the
ARISER randomized clinical trial. AMA Oncology. 2017;3:913-920.
7. Haas NB, Manola , Uzzo RG, et al. Adjuvant sunitinib or sorafenib
for high-risk, non-metastatic renal-cell carcinoma (ECG-ACRIN E2805):
a double-blind, placebo-controlled, randomized, phase 3 trial. Lancet.
2016;387:2008-2016.
8. Lenis AT, Donin NM, Johnson DC, et al. Adjuvant therapy for high
risk localized kidney cancer: emerging evidence and future clinical trials.
J Urol. 2018;199:43-52.
9. Motzer RJ, Ravaud A, Patard J-J, et al. Adjuvant sunitinib for highrisk
renal cell carcinoma after nephrectomy: subgroup analyses and updated
overall survival results. Eur Urol. 2018;73:62-68.
10. Staehler M, Motzer RJ, George DJ, et al. Adjuvant sunitinib in patients
with high-risk renal cell carcinoma: safety, therapy management,
and patient-reported outcomes in the S-TRAC trial. Annals of Oncology,
mdy329, https://doi.org/10.1093/annonc/mdy329
11. George DJ et al. Immune Biomarkers Predictive for Disease-Free Survival
with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma:
From Randomized Phase III S-TRAC Study. Clin Cancer Res. 2018
Apr 1;24(7):1554-1561. https://www.ncbi.nlm.nih.gov/pubmed/2937
4054
12. Giraldo NA, Becht E, Pages F, et al. Orchestration and prognostic significance
of immune checkpoints in the microenvironment of primary
and metastatic renal cell cancer. Clin Cancer Res. 2015;21:3031-3040.
13. McDermott DF, Atkins MB, Motzer RJ, et al. A phase II study of atezolizumab
(atezo) with or without bevacizumab (bev) versus sunitinib
(sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).
J Clin Oncol. 2017;35:(suppl 6S; abstr 431).
14. Choueiri TK, Larkin JMG, Oya M, et al. First-line avelumab þ axitinib
therapy in patients (pts) with
advanced renal cell carcinoma (aRCC): results from a phase 1b trial. J
Clin Oncol. 20177;35(suppl. Abstract 4504).
15. Escudier BJ, Riniu BI, Martini JF, et al. Phase III trial of adjuvant sunitinib
in patients with high-risk renal cell carcinoma (RCC): validation
of the 1-gene Recurrence Score in stage III patients. J Clin Oncol.
2017;35;no.15_suppl (abstr 4508).
16. Sun M, Marconi L, Eisen T, et al. Eur Urol. 2018 May https://www.
ncbi.nlm.nih.gov/pubmed/29784193
17. Sternberg CN, Donskov F, Haas NB, et al. Pazopanib exposure relationship
with clinical efficacy and safety in the adjuvant treatment of
advanced renal cell carcinoma. Clin Cancer Res.2018;24:3005-3013.
18.https://www.pfizer.com/news/press-release/press-release
detail/pfizer_provides_update_on_phase_3_trial_of_axitinib_as_adjuvant_
treatment_for_patients_at_high_risk_of_renal_cell_carcinoma_recurrence_
after_surgery. KCJ
• Active Surveillance of Small Renal Masses:
Redefining a Safe Management Strategy for
Select Patients
• Highlights, Analyses from the 17th International
Kidney Cancer Symposium, Nov. 2-3
Kidney Cancer Journal,
Now in Its 16th Year